

Recombinant Human LR3-IGF-1

Catalog No : PMK2153

Known As: Insulin-Like Growth Factor I; IGF-I; Mechano Growth Factor; MGF; Somatomedin-C; IGF1; IBP1

PROPERTIES

Description	Recombinant Human LR3 Insulin-Like Growth Factor-I is produced by our E.coli expression system and the target gene encoding Gly49-Ala118 is expressed. .
Accession	P05019
Formulation	Lyophilized from a 0.2 µm filtered solution of 20mM NaAc-HAc, 4% Mannitol, pH 4.5.
Size	10µg/50µg/500µg/1mg
Purity	> 95%
Endotoxin	< 1 EU/µg as determined by LAL test.
Predicted Mol Mass	9.1 KDa
Apparent Mol Mass	11 KDa, reducing conditions
Reconstitution	Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100µg/ml. Dissolve the lyophilized protein in 50mM Acetic Acid. Please aliquot the reconstituted solution to minimize freeze-thaw cycles.
Shipping	The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature listed below.
Storage	Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months.
Background	Insulin-like growth factor I (IGF1) belongs to the family of insulin-like growth factors that are structurally homologous to proinsulin. Mature IGFs are generated by proteolytic processing of inactive precursor proteins, which contains the N- and Cterminal propeptide regions. Mature human IGF-I consisting of 70 amino acids has 94% identity with mouse IGF-I and exhibits cross-species activity. IGF-1 binds IGF-IR, IGF-IIR, and the insulin receptor and plays a key role in cell cycle progression, cell proliferation and tumor progression. IGF-1 expression is regulated by growth hormone. R3 IGF-1 is an 83 amino acid analog of IGF-1 comprising the complete human IGF-1 sequence with the substitution of an Arg (R) for the Glu(E) at position three, hence R3, and a 13 amino acid extension peptide at the N terminus. R3 IGF-1 has been produced with the purpose of increasing biological activity. R3 IGF-1 is significantly more potent than human IGF-I in vitro.

NOTE:The product listed herein is for research use only and is not intended for use in human or clinical diagnosis. Suggested applications of our products are not recommendations to use our products in violation of any patent or as a license. We cannot be responsible for patent infringements or other violations that may occur with the use of this product.